Prudential Financial Inc Chinook Therapeutics, Inc. Transaction History

Prudential Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $8,210 - $16,975	440 Added 3.6%	12,673 $486,000
Q1 2023 May 12, 2023	SELL	$21.53 - $26.8 $430 - $536	-20 Reduced 0.16%	12,233 $283,000
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $122,585 - $179,963	-6,580 Reduced 34.94%	12,253 $0
Q3 2022 Nov 04, 2022	BUY	$17.51 - $23.37 $6,828 - $9,114	390 Added 2.11%	18,833 $370,000
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $232,197 - $346,728	18,443 New	18,443 $323,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.